Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03129451 · ClinicalTrials.gov registry record
The Microbiome in Parkinson's Disease
A clinical trial, sponsored by Corewell Health West.
- Completed
- Registry status
- 23
- Enrollment target
NCT03129451: Completed study, sponsored by Corewell Health West.
NCT03129451 is a clinical trial that has completed, run by Corewell Health West. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03129451 has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
To investigate the dynamic relationship between the intestinal microbiota and Inflammation in subjects with Parkinson's disease.
Primary Outcome
Differences in microbiome abundance will be detected using a Kruskal-Wallis' test generating a Benjamini-Hochberg false discovery rate (FDR)-corrected P value (\<0.05 for significance). For the microbiome analysis, in silico community functional predictions will be performed using PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) and significant differences in Kyoto Encyclopedia of Genes and Genomes (KEGG) ortholog (KO) abundances between groups will be i
Interventions
- DIAGNOSTIC_TEST Microbiome specimens in stool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-04-17 |
| Est. Completion | 2021-01-07 |
What the finished NCT03129451 record still lists
NCT03129451 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Microbiome specimens in stool is the first listed.
NCT03129451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03129451 about?
NCT03129451 is a clinical study titled "The Microbiome in Parkinson's Disease". To investigate the dynamic relationship between the intestinal microbiota and Inflammation in subjects with Parkinson's disease.
What is the current status of trial NCT03129451?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2017-04-17. Estimated completion is 2021-01-07.
What interventions are being tested in trial NCT03129451?
The interventions under investigation include: Microbiome specimens in stool (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03129451?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI